Prognostic factors for patients with advanced renal cell carcinoma (aRCC) in the era of first-line (1L) treatment with immune checkpoint inhibitors (ICIs).

被引：0

作者：

Mantia, Charlene

Jegede, Opeyemi

Regan, Meredith M.

Atkins, Michael B.

McDermott, David F.

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Int Breast Canc Study Grp, Boston, MA USA

[3] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[4] Harvard Canc Ctr, Dana Farber, Beth Israel Deaconess Med Ctr, Boston, MA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4544

引用

页数：1